GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2007

CHDI to Leverage ActiveSight’s Fragment-Based Lead Discovery Know-How for Huntington's

  • ActiveSight will collaborate on a fragment-based lead discovery (FBLD) project with CHDI related to Huntington's disease (HD). The companies hope that the FBLD approach will lead to therapies in shorter time periods than conventional methods.

    ActiveSight will screen libraries using x-ray crystallography to visualize fragments that bind to a CHDI-selected HD target. The fragments will then be linked or grown into larger, drug-like compounds. These are thought to be more efficiently binding than compounds resulting from HTS methodologies, according to the firms.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?